Comparative Clinical and Economic Outcomes among Venous Thromboembolism Patients who Initiated Apixaban or Warfarin in the United States Medicare Population (VTE CER in Medicare)

Study identification

• EU PAS number:
  EUPAS24902
• Study ID:
  35610
• Official title and acronym:
  Comparative Clinical and Economic Outcomes among Venous Thromboembolism Patients who Initiated Apixaban or Warfarin in the United States Medicare Population (VTE CER in Medicare)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This study will evaluate the patient profiles, current antithrombotic patterns, and real-world clinical & economic outcomes among patients with VTE
• Study status:
  Finalised

Study timelines

Date when funding contract was signed

Actual: 11/09/2017

Study start date

Planned: 01/08/2018

Actual: 08/01/2018

Date of final study report

Planned: 02/06/2020

Actual: 02/06/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable